New orders further support Creso Pharma’s 700% share price gain
Creso Pharma Limited (ASX:CPH; FRA: 1X8) continues to build on a fortnight of strong news flow with its wholly-owned Canadian subsidiary, Mernova Medicinal Inc. receiving three purchase orders with a combined value of C$275,023 (A$288,159).
Further to this was the receipt of a Notice to Purchase from the Province of Ontario, marking the company’s entry into Canada’s largest recreational cannabis market.
The first purchase order valued at C$232,826 (A$243,841) is from Truro Cannabis Company, a licensed producer of medical and recreational cannabis products.
Such has been the quality of the news flow that CPH's shares closed at a 12 month high of 23.5 cents yesterday, up 700% from 3.1 cents a fortnight ago.
Positive company-specific and industry news has underpinned the sharp share price gain, including significant developments on the regulatory front that are likely to benefit Creso Pharma across key markets such as the US and the European Union.
It is worth noting that in the next week it will be Australia’s turn to release important regulatory news regarding its potential rerating of medicinal CBD as an over-the-counter (OTC) product.
Creso Pharma’s premium products gaining recognition
The Truro order is a bulk order for three of Mernova’s high quality, indoor grown, hand trimmed, hang dried, cured, artisanal cannabis strains, in dried flower form, specifically HPG13, Lemon Haze and Mimosa.
The group has an established presence across Canada, and will sell Mernova’s products through their well-established distribution channels.
Creso Pharma also received a maiden purchase order from the Yukon Liquor Corporation (‘Yukon’), opening a new Canadian market with the company anticipating further orders in the future.
The purchase order for the HPG13, Lemon Haze and Mimosa strains, in dried flower form is valued at C$24,333 (A$25,436).
These products will be sold under the Ritual Green brand in 3.5 gram and 7 gram units, through leading retailer Triple J’s Canna Space.
These developments serve as confirmation of the significant demand for Mernova’s high-quality cannabis products in the rapidly growing Canadian retail recreational market.
Commenting on these recent developments and expressing his confidence regarding the likelihood of further strong order flow, Mernova managing director Jack Yu said, “Mernova continues to make very strong progress in the Canadian recreational market.
‘’The three most recently secured purchase orders will contribute to Creso Pharma’s growing revenue profile and we expect additional orders to materialise in the very near term.
“Mernova has now become part of a very select group of licensed producers with cannabis products for sale in the Yukon.
‘’This is a major achievement for us, and we expect growth to continue across Canada and, with our pending entry into Ontario, Canada’s largest recreational market, we expect rapid growth to continue.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.